Physician profile
Jay M Jones
NPI 1740235308
$1,165.19
in general payments reported to CMS, 2019-2025
21 companies · $317 in 2025
The $317 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $146 · 2020: $29.25 · 2021: $86.35 · 2022: $285 · 2023: $201 · 2024: $101 · 2025: $317.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $619.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $618.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $209.42 | 2021-2025 | |
| Pfizer INC. | $202.15 | 2019-2025 | |
| Novo Nordisk INC | $108.72 | 2019-2024 | Ozempic, Rybelsus |
| Astellas Pharma US INC | $106.04 | 2019-2023 | Veozah |
| Amgen INC. | $105.97 | 2019-2025 | Otezla, Repatha |
| Abbott Laboratories | $70.56 | 2025 | Freestyle Libre 3, Esprit |
| Glaxosmithkline, LLC. | $59.96 | 2023-2025 | Shingrix, Arexvy, Bexsero |
| Madrigal Pharmaceuticals | $45.38 | 2024-2025 | Rezdiffra, Resmetirom |
| Idorsia Pharmaceuticals US INC | $30.45 | 2023 | Quviviq |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $30.06 | 2022-2023 | Xifaxan |
| Mayne Pharma Commercial LLC | $27.46 | 2023 | |
| Sumitomo Pharma America, INC. | $23.44 | 2025 | Gemtesa |
| Amarin Pharma, INC. | $21.03 | 2022 | |
| Gilead Sciences, INC. | $19.79 | 2025 | |
| Otsuka America Pharmaceutical, INC. | $19.69 | 2025 | Rexulti |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $16.04 | 2025 | O-Arm |
| Astrazeneca Pharmaceuticals LP | $15.54 | 2022 | |
| Antares Pharma, INC. | $14.22 | 2025 | Xyosted |
| Acella Pharmaceuticals, LLC | $13.87 | 2023 | NP Thyroid 60 |
| Bayer Healthcare Pharmaceuticals INC. | $13.14 | 2021 | |
| Allergan, INC. | $12.26 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jay Jones listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.